SEC EDGARAUG 201 min read$CAH

WEITZMAN DEBORAH sold $1.7M of CAH

WEITZMAN DEBORAH (CEO, PSS Segment) sold 7,354 shares of CARDINAL HEALTH INC (CAH) at an average of $235.45 ($235.30–$237.44, $1.73M total) across 3 trades on 2026-08-18.

Original reporting

SEC EDGAR · WEITZMAN DEBORAH

Published Aug 20, 2026, 11:30 AM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 20, 2026, 11:38 AM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefInsider activity

Primary signal

$CAH

Bearish

medium confidence

Mentioned

$CAH

Relevance

6/10

alphai data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$CAHBearishLow

Why it matters

The disclosed sale adds a small negative data point but is unlikely to shift broader market sentiment.

Market read

Limited relevance; primarily of interest to shareholders monitoring insider activity.

What to watch

CEO may be diversifying personal portfolio; no change in company fundamentals.

Relevance 6/10Novelty 3/10Timing: filing date 2026-08-20

Background

Form 4 filing discloses insider transactions; provides transparency for shareholders.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CAHBearishMedium confidence

Context

CEO Deborah Weitzman sold 7,354 shares for $1.73M via open‑market trades on 2026‑08‑18.

Expected impact

Potential short‑term dip of 0.5‑1% as market digests the sale.

Evidence & confidence

Sale size is modest relative to holdings, but CEO disposition can influence sentiment.

Market effects

Sector

Minimal impact on healthcare distribution sector; similar insider sales have not moved the sector.

Regional

U.S. market only; no regional ripple.

Global

Low; limited to Cardinal Health investors.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event, not a bearish signal.

Key entities

Company
Cardinal Health Inc.
U.S. healthcare services and products distributor.
Executive
Deborah Weitzman
CEO of the PSS segment at Cardinal Health.

Read at source ← All news

SEP 7

$CAHMedAI 8/10

4 companies on verge of settling US opioid lawsuits

AmerisourceBergen, Cardinal Health, McKesson, and Johnson & Johnson are nearing a $26B settlement for opioid lawsuits. New York reached a separate $1B deal with the distributors. Johnson & Johnson will contribute up to $5B nationally. Trials continue elsewhere.

pressdemocrat.com3 min

SEP 3

$CAHHighAI 8/10

Jim Cramer Notes Cardinal Health (CAH) is “Too Attractive to Ignore”

Jim Cramer highlighted Cardinal Health (CAH) as a favorite, citing its specialty pharmaceuticals and healthcare services growth. Q4 revenue rose 6% to $63.7B but missed estimates, while adjusted EPS was $2.91. Fiscal 2027 guidance includes non-GAAP EPS of $12.40-$12.60 and adjusted free cash flow of $3.5B-$4B. Risks include execution, drug pricing, and customer concentration.

insidermonkey.com3 min

AUG 20

$CAHMed

Hollar Jason M. sold $29.4M of CAH

Hollar Jason M. (Chief Executive Officer) sold 124,529 shares of CARDINAL HEALTH INC (CAH) at an average of $235.89 ($233.22–$237.88, $29.38M total) across 10 trades over 2026-08-18 to 2026-08-19.

SEC EDGAR1 min

AUG 19

$CAHHighAI 8/10

Cardinal Health’s (CAH) Big Earnings Beat Hides a More Complicated Story

Cardinal Health (CAH) reported Q4 2026 earnings with non-GAAP EPS up 40% YoY to $2.91, including a $0.31 one-time tariff refund. Revenue reached $63.7B, up 6% YoY. Full-year adjusted free cash flow hit $5B. Guidance suggests slower growth ahead. The company expanded its buyback program by $5B to $6.4B.

yahoo.com2 min

AUG 18

$CAHHighAI 9/10

Cardinal Health (CAH) Q4 2026 Earnings Call Transcript

Cardinal Health (CAH) reported Q4 2026 revenue of $63.7B, up 6%, driven by Pharmaceutical and Specialty Solutions. Non-GAAP EPS was $2.91, up 40%. Fiscal 2027 guidance includes 3-5% pharma revenue growth and 8-11% profit growth. The company plans $1B in share repurchases and increased its authorization to $6.4B. Management cited risks from geopolitical instability and IRA price changes.

fool.com6 min